US FDA approves Takeda’s Livtencity to treat people with post-transplant Cytomegalovirus infection
In the phase-III Solstice study, more than twice the proportion of adult transplant recipients with refractory or resistant (R/R)…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.